What is the significance of a raised IgG (18.30 g/L) with plasma viscosity (1.77 cP) in a patient who has a persistent irregular right upper‑lobe juxta‑mediastinal and subpleural mass that decreased from 4.5 cm to 3.8 cm but now shows a new posterior‑superior component, along with multiple smaller PET‑avid nodules in the right upper lobe?

Urgent Tissue Diagnosis Required for Suspected Malignancy with Concerning Features

This presentation strongly suggests malignancy (likely primary lung cancer or IgG4-related disease) and requires immediate tissue diagnosis via percutaneous or surgical biopsy to guide definitive treatment. The combination of PET-avid pulmonary masses with new nodular components, despite partial size reduction, demands histopathological confirmation before any therapeutic decisions.

Clinical Significance of Laboratory Findings

The raised IgG (18.30 g/L, reference ~7-16 g/L) with plasma viscosity of 1.77 cP (reference 1.5-1.72 cP) is mildly elevated but not in the range typically causing hyperviscosity syndrome, which usually manifests at viscosity ≥4-5 cP 1, 2. However, these findings raise two critical differential diagnoses:

Primary Concern: Lung Malignancy

• PET-avid irregular mass with new posterior-superior component despite size reduction is highly suspicious for lung cancer 3, 4, 5
• Multiple smaller PET-avid nodules suggest either:
  • Intrapulmonary metastases (T4 disease)
  • Synchronous primary tumors
  • Satellite lesions
• The juxta-mediastinal location and irregular morphology increase malignancy probability

Alternative Diagnosis: IgG4-Related Disease

The elevated IgG with pulmonary masses raises the possibility of IgG4-related lung disease (IgG4-RLD), which can mimic lung cancer radiologically 6, 7, 8. Key features supporting this:

• IgG4-RLD can present as pulmonary pseudotumors with PET avidity (SUVmax up to 6.68) 7
• Can cause multiple nodules and pleural involvement 9
• Responds dramatically to corticosteroids 6, 7, 8

However, serum IgG4 levels must be specifically measured (not just total IgG) to evaluate this diagnosis, as total IgG elevation alone is insufficient 6, 7.

Immediate Diagnostic Algorithm

Step 1: Obtain Tissue Diagnosis (Priority)

Percutaneous lung biopsy is rated 8/9 (usually appropriate) for masses of this size with malignancy concern 3. The guidelines are explicit:

• For masses >1.5 cm with high malignancy probability: percutaneous biopsy rated 8/9 3
• Cutting needle biopsy (CNB) preferred over fine needle aspiration to distinguish benign from malignant and provide histological architecture 4
• The juxta-mediastinal location is accessible to percutaneous approach 4

If percutaneous biopsy is non-diagnostic or technically difficult, proceed directly to surgical biopsy/resection 3, 4.

Step 2: Additional Laboratory Testing

Order immediately:

• Serum IgG4 levels (specific measurement, not just IgG subfractions)
• Serum protein electrophoresis with immunofixation to exclude plasma cell dyscrasia
• Complete blood count, comprehensive metabolic panel
• Serum β2-microglobulin and LDH if plasma cell disorder suspected

Step 3: Histopathological Evaluation Must Include

The biopsy specimen requires:

• Standard H&E staining for morphology
• IgG4 immunohistochemistry with IgG4/IgG ratio (>40% IgG4+ plasma cells and >50 IgG4+ cells/HPF suggests IgG4-RD) 6, 7, 8
• Storiform fibrosis pattern assessment
• Malignancy markers as appropriate

Management Based on Diagnosis

If Malignancy Confirmed:

• Each nodule must be evaluated individually - do not assume all are metastatic without histopathological confirmation 10
• The presence of additional nodules does not automatically preclude curative treatment 10
• Staging workup per ACCP guidelines: contrast-enhanced chest CT, PET/CT for extrathoracic staging, invasive mediastinal staging 5
• Multidisciplinary tumor board discussion mandatory 4

If IgG4-RD Confirmed:

• Initiate high-dose corticosteroids (prednisolone 0.6-1 mg/kg/day, typically 40-60 mg daily) 6, 7, 8
• Expect rapid clinical and radiological response within 2-6 weeks 6, 7
• Consider steroid-sparing agents (azathioprine, mycophenolate) for maintenance 8
• Monitor serum IgG4 levels and repeat imaging

Critical Pitfalls to Avoid

1. Do not delay biopsy for additional imaging - PET avidity in masses >3 cm with irregular features demands tissue diagnosis 3, 4

2. Do not assume all nodules are metastatic - this could deny potentially curative surgery. Guidelines explicitly state curative treatment should not be denied without histopathological confirmation of metastasis 10

3. Do not rely on size reduction as evidence of benign disease - the new posterior-superior component despite overall size decrease is concerning for evolving malignancy or treatment-resistant disease

4. Do not measure only total IgG - specific IgG4 levels are required to evaluate IgG4-RD 6, 7

5. The plasma viscosity of 1.77 cP does not cause symptoms and is not the primary concern here 1, 2. Hyperviscosity syndrome requires viscosity ≥4-5 cP with corresponding IgG >40 g/L, IgA >60 g/L, or IgM >30 g/L.

Bottom Line

Proceed immediately to percutaneous or surgical lung biopsy 3, 4. The PET-avid irregular mass with evolving morphology and multiple additional nodules represents either lung cancer requiring staging and treatment, or IgG4-RLD requiring immunosuppression. The mildly elevated IgG and plasma viscosity are insufficient to cause symptoms but raise IgG4-RLD as a differential diagnosis that can only be confirmed histologically. Time-sensitive tissue diagnosis is mandatory - surveillance imaging is inappropriate for this presentation 3.